ARROWHEAD PHARMACEUTICALS, INC. Payments to Acquire Marketable Securities
ARROWHEAD PHARMACEUTICALS, INC. (ARWR) reported Payments to Acquire Marketable Securities of $193.96 million for the 9-month period ending 2020-06-30, per its 10-Q filed 2020-08-05.
Discontinued › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireMarketableSecurities · last filed 2020-08-05
- ARROWHEAD PHARMACEUTICALS, INC. payments to acquire marketable securities for the quarter ending 2020-06-30 was $13.44M.
- ARROWHEAD PHARMACEUTICALS, INC. payments to acquire marketable securities for the quarter ending 2019-09-30 was $0.00, a 100.00% decline year-over-year.
- ARROWHEAD PHARMACEUTICALS, INC. payments to acquire marketable securities for the quarter ending 2019-06-30 was $0.00, a 100.00% decline year-over-year.
- ARROWHEAD PHARMACEUTICALS, INC. payments to acquire marketable securities for the quarter ending 2019-03-31 was $21.00M.
- ARROWHEAD PHARMACEUTICALS, INC. payments to acquire marketable securities for fiscal 2019 was $90.27M, a 73.31% increase from fiscal 2018.
- ARROWHEAD PHARMACEUTICALS, INC. payments to acquire marketable securities for fiscal 2018 was $52.08M, a 15.81% increase from fiscal 2017.
- ARROWHEAD PHARMACEUTICALS, INC. payments to acquire marketable securities for fiscal 2017 was $44.97M.
- ARROWHEAD PHARMACEUTICALS, INC. payments to acquire marketable securities for fiscal 2014 was $46.37M, a 332.01% increase from fiscal 2013.
| Period end | Payments to Acquire Marketable Securities 3 month | Payments to Acquire Marketable Securities 6 month | Payments to Acquire Marketable Securities 9 month | Payments to Acquire Marketable Securities 12 month | Payments to Acquire Marketable Securities 98 month | Payments to Acquire Marketable Securities 101 month | Payments to Acquire Marketable Securities 104 month | Payments to Acquire Marketable Securities 107 month | Payments to Acquire Marketable Securities 110 month | Payments to Acquire Marketable Securities 113 month | Payments to Acquire Marketable Securities 116 month | Payments to Acquire Marketable Securities 119 month | Payments to Acquire Marketable Securities 122 month | Payments to Acquire Marketable Securities 125 month | Payments to Acquire Marketable Securities 128 month | Payments to Acquire Marketable Securities 131 month |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2020-06-30 | $13.44M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-08-05 | $193.96M 10-Q · filed 2020-08-05 | ||||||||||||||
| 2020-03-31 | $180.52M 10-Q · filed 2020-05-07 | |||||||||||||||
| 2019-09-30 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2019-11-25 | $0.00 derived: sum of 2 quarters · filed 2020-08-05 | $21.00M derived: sum of 3 quarters · filed 2020-08-05 | $90.27M 10-K · filed 2019-11-25 | ||||||||||||
| 2019-06-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2020-08-05 | $21.00M derived: sum of 2 quarters · filed 2020-08-05 | $90.27M 10-Q · filed 2020-08-05 | $95.17M derived: sum of 4 quarters · filed 2020-08-05 | ||||||||||||
| 2019-03-31 | $21.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-05-07 | $90.27M 10-Q · filed 2020-05-07 | $95.17M derived: sum of 3 quarters · filed 2020-05-07 | $137.33M derived: sum of 4 quarters · filed 2020-05-07 | ||||||||||||
| 2018-12-31 | $69.27M 10-Q · filed 2020-02-05 | $74.18M derived: sum of 2 quarters · filed 2020-02-05 | $116.34M derived: sum of 3 quarters · filed 2020-02-05 | $116.34M derived: sum of 4 quarters · filed 2020-02-05 | ||||||||||||
| 2018-09-30 | $4.91M derived: 10-K 12 month − 10-Q 9 month · filed 2019-11-25 | $47.07M derived: sum of 2 quarters · filed 2019-11-25 | $47.07M derived: sum of 3 quarters · filed 2019-11-25 | $52.08M 10-K · filed 2019-11-25 | ||||||||||||
| 2018-06-30 | $42.16M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-08-05 | $42.16M derived: sum of 2 quarters · filed 2019-08-05 | $47.17M 10-Q · filed 2019-08-05 | $52.24M derived: sum of 4 quarters · filed 2019-11-25 | ||||||||||||
| 2018-03-31 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2019-05-08 | $5.02M 10-Q · filed 2019-05-08 | $10.09M derived: sum of 3 quarters · filed 2019-11-25 | $25.15M derived: sum of 4 quarters · filed 2019-11-25 | ||||||||||||
| 2017-12-31 | $5.02M 10-Q · filed 2019-02-07 | $10.09M derived: sum of 2 quarters · filed 2019-11-25 | $25.15M derived: sum of 3 quarters · filed 2019-11-25 | |||||||||||||
| 2017-09-30 | $5.07M derived: 10-K 12 month − 10-Q 9 month · filed 2019-11-25 | $20.13M derived: sum of 2 quarters · filed 2019-11-25 | $44.97M 10-K · filed 2019-11-25 | |||||||||||||
| 2017-06-30 | $15.06M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-08-07 | $39.90M 10-Q · filed 2018-08-07 | ||||||||||||||
| 2017-03-31 | $24.85M 10-Q · filed 2018-05-08 | |||||||||||||||
| 2014-09-30 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2016-12-14 | $0.00 derived: sum of 2 quarters · filed 2016-12-14 | $27.29M derived: sum of 3 quarters · filed 2016-12-14 | $46.37M 10-K · filed 2016-12-14 | ||||||||||||
| 2014-06-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2015-08-04 | $27.29M derived: sum of 2 quarters · filed 2015-08-04 | $46.37M 10-Q · filed 2015-08-04 | $53.04M derived: sum of 4 quarters · filed 2015-12-14 | ||||||||||||
| 2014-03-31 | $27.29M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-05-11 | $46.37M 10-Q · filed 2015-05-11 | $53.04M derived: sum of 3 quarters · filed 2015-12-14 | $75.67M 10-Q · filed 2014-05-06 | ||||||||||||
| 2013-12-31 | $19.08M 10-Q · filed 2015-02-09 | $25.75M derived: sum of 2 quarters · filed 2015-12-14 | $48.38M 10-Q · filed 2014-02-04 | |||||||||||||
| 2013-09-30 | $6.67M derived: 10-K 12 month − 10-Q 9 month · filed 2015-12-14 | $10.73M 10-K · filed 2015-12-14 | $29.31M 10-K · filed 2013-12-18 | |||||||||||||
| 2013-06-30 | $4.06M 10-Q · filed 2014-08-12 | $22.63M 10-Q · filed 2013-08-07 | ||||||||||||||
| 2013-03-31 | $18.58M 10-Q · filed 2013-05-09 | |||||||||||||||
| 2012-12-31 | $18.58M 10-Q · filed 2013-02-13 | |||||||||||||||
| 2012-09-30 | $18.58M 10-K · filed 2012-12-28 | |||||||||||||||
| 2012-06-30 | $18.58M 10-Q · filed 2012-08-13 | |||||||||||||||
| 2012-03-31 | $18.58M 10-Q · filed 2012-05-08 | |||||||||||||||
| 2011-12-31 | $18.58M 10-Q · filed 2012-02-09 | |||||||||||||||
| 2011-09-30 | $18.58M 10-Q · filed 2012-08-13 | |||||||||||||||
| 2011-06-30 | $18.58M 10-Q · filed 2011-08-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 |